Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube, Robert A. Anders, Geoffrey D. Young, et al.
Science Translational Medicine (2012) Vol. 4, Iss. 127
Open Access | Times Cited: 2008

Showing 1-25 of 2008 citing articles:

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2443-2454
Open Access | Times Cited: 11756
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2455-2465
Open Access | Times Cited: 7481
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith, et al.
Science (2017) Vol. 357, Iss. 6349, pp. 409-413
Open Access | Times Cited: 5711
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 21, pp. 2018-2028
Open Access | Times Cited: 5638
Cancer immunotherapy using checkpoint blockade
Antoni Ribas, Jedd D. Wolchok
Science (2018) Vol. 359, Iss. 6382, pp. 1350-1355
Open Access | Times Cited: 5337
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, et al.
Nature (2014) Vol. 515, Iss. 7528, pp. 563-567
Open Access | Times Cited: 4813
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo, et al.
Cell (2017) Vol. 168, Iss. 4, pp. 707-723
Open Access | Times Cited: 4390
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 2, pp. 122-133
Open Access | Times Cited: 4097
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll
Cancer Cell (2015) Vol. 27, Iss. 4, pp. 450-461
Open Access | Times Cited: 3733
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski, Hans Schreiber, Yang‐Xin Fu
Nature Immunology (2013) Vol. 14, Iss. 10, pp. 1014-1022
Open Access | Times Cited: 3645
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 8, pp. 2930-2940
Open Access | Times Cited: 2977
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
The Lancet (2016) Vol. 387, Iss. 10030, pp. 1837-1846
Closed Access | Times Cited: 2565
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 5, pp. 275-287
Open Access | Times Cited: 2396
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Janis M. Taube, Alison Klein, Julie R. Brahmer, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 19, pp. 5064-5074
Open Access | Times Cited: 2208
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2137
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian, Mario Sznol, David F. McDermott, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 10, pp. 1020-1030
Open Access | Times Cited: 2100
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, et al.
Cell (2017) Vol. 171, Iss. 4, pp. 934-949.e16
Open Access | Times Cited: 1893
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman, Laurence Zitvogel, Catherine Sautès‐Fridman, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 12, pp. 717-734
Closed Access | Times Cited: 1885
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 21, pp. 1976-1986
Open Access | Times Cited: 1804
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe, Kristen E. Pauken
Nature reviews. Immunology (2017) Vol. 18, Iss. 3, pp. 153-167
Closed Access | Times Cited: 1569
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Stefani Spranger, Robbert M. Spaapen, Yuanyuan Zha, et al.
Science Translational Medicine (2013) Vol. 5, Iss. 200
Open Access | Times Cited: 1534
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 3, pp. 151-167
Closed Access | Times Cited: 1426
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui, Jeanne Cheung, Jing Zhu, et al.
Science (2017) Vol. 355, Iss. 6332, pp. 1428-1433
Open Access | Times Cited: 1396
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi, Julien Mazières, David Planchard, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 3, pp. 257-265
Open Access | Times Cited: 1370
Page 1 - Next Page

Scroll to top